Immunological basis of genesis of hepatocellular carcinoma: unique challenges and potential opportunities through immunomodulation
File(s)vaccines-08-00247-v2.pdf (1.96 MB)
Published version
Author(s)
Type
Journal Article
Abstract
A majority of hepatocellular carcinoma (HCC) develops in the setting of persistent chronic inflammation as immunological mechanisms have been shown to play a vital role in the initiation, growth and progression of tumours. The index review has been intended to highlight ongoing immunological changes in the hepatic parenchyma responsible for the genesis and progression of HCC. The in-situ vaccine effect of radiofrequency (RF) is through generation tumour-associated antigens (TAAs), following necrosis and apoptosis of tumour cells, which not only re-activates the antitumour immune response but can also act in synergism with checkpoint inhibitors to generate a superlative effect with intent to treat primary cancer and distant metastasis. An improved understanding of oncogenic responses of immune cells and their integration into signaling pathways of the tumour microenvironment will help in modulating the antitumour immune response. Finally, we analyzed contemporary literature and summarised the recent advances made in the field of targeted immunotherapy involving checkpoint inhibitors along with RF application with the intent to reinstate antitumour immunity and outline future directives in very early and early stages of HCC.
Date Issued
2020-05-23
Date Acceptance
2020-05-22
Citation
Vaccines, 2020, 8
ISSN
2076-393X
Publisher
MDPI AG
Journal / Book Title
Vaccines
Volume
8
Copyright Statement
© 2020 by the authors. Licensee MDPI, Basel, Switzerland. This article is an open access
article distributed under the terms and conditions of the Creative Commons Attribution
(CC BY) license (http://creativecommons.org/licenses/by/4.0/).
article distributed under the terms and conditions of the Creative Commons Attribution
(CC BY) license (http://creativecommons.org/licenses/by/4.0/).
Subjects
carcinoma
checkpoint inhibitors
hepatocellular
immunomodulation
radiofrequency
Publication Status
Published
Article Number
ARTN 247